Kymera Therapeutics, Inc. (KYMR) announced that its investigational New Drug (IND) application for pipeline candidate, KT-621, has been cleared by the FDA. KT-621 is an investigational first-in-class once-daily, oral STAT6 degrader with dupilumab-like activity in preclinical models and the potential to address multiple allergic and atopic diseases, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease. KYMR's Plans for KT-621 Following the IND clearance, KYMR expects to initiate dos ...